Slide 1: March Quarter Investor Video Presentation
ASX RELEASE. 5 May 2026 March Quarter Investor Video Presentation Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”), a leader in innovative mental health treatments, is pleased to provide a March Quarter Video Presentation delivered by Executive Chairman Greg Hutchinson and Chief Operating Offi
Slide 2: ASX Release
ASX RELEASE Emyria Limited develops and delivers new treatments for mental health and select neurological conditions through an integrated model of direct clinical services and treatment development: Emyria Healthcare: Evidence-based treatment for patients not finding relief from conventional care w
Slide 3: March Quarter Presentation
ASX : EMD March Quarter Presentation Investor Update May 2026
Slide 4: Disclaimer
Disclaimer This presentation has been prepared by Emyria Limited ACN 625 085 734 (Company or Emyria). This presentation is not a financial product or investment advice or recommendation, offer or invitation by any person or to any person to sell or purchase securities in Emyria in any jurisdiction. T
Slide 5: Emyria | March Quarterly Highlights
Emyria | March Quarterly Highlights Revenue growth - $1.2m for the quarter Durable Clinical Outcomes in PTSD program 12 months post treatment. 76% of patients achieving clinically significant improvement 67% patients remained in remission First Victorian Clinic on track for Q2 FY26 Commencement Subse
Slide 6: Significant Global Research in Psychedelic Drugs
Significant Global Research in Psychedelic Drugs Many psychedelic-assisted therapy programs currently in development globally1 EMD uniquely positioned to Psyence Biomed support these companies through existing clinical network from clinical trial execution to post approval commercial roll-out2 1. Psy
Slide 7: Significant Global Research in Psychedelic Drugs
Significant Global Research in Psychedelic Drugs 1. https://psychedelics.berkeley.edu/clinical-trials-map 5 Advanced therapies. Compassionate care.
Slide 8: Regulatory Catalysts
Regulatory Catalysts Step Description Emyria’s Mitigation Authorised Prescribers Extended Per-prescriber approvals Established HREC relationship & Achieved (APs) timeframes process dedicated AP applications team. In discussion Curent limits on which disciplines Active advocacy to broaden Not achieve
Slide 9: New: Empax Clinic utilisation increasing
New : Empax Clinic utilisation increasing 7 Advanced therapies. Compassionate care.
Slide 10: Emyria | Future Catalysts
Emyria (ASX:EMD) | Future Catalysts Target activities Grow capacity nationally New indications to via new site partners then expand total addressable Optimise utilisation of markets clinics Expand funded programs Add new drug partners to with new payers Global Partnership Program 8 20 Advanced Advan
Slide 11: Emyria | Why Invest
Emyria | Why Invest Significant Total Operationalised the First mover advantage Addressable Market delivery of PAT at Scale globally globally Capital Light approach Delivering durable Generating revenue to clinics expansion outcomes 9 Advanced therapies. Compassionate care.
Slide 12: Emyria Board
Emyria Board Significant Clinical Services & Global Innovation Expertise Greg Hutchinson Dr Michael Winlo Dr Karen Smith Dr Mohit Kaushal Prof Sir John Executive Chairman Executive Director Non-Executive Non-Executive Tooke Director Director Non-Executive Health Service Research & Data Biopharma Exec
Slide 13: Contact Information
Contact Information Greg Hutchinson ghutchinson@emyria.com Mary-Ann Rennie mrennie@emyria.com Investor / Visit Our Media Inquiries Investor Hub investors@emyria.com